Form 4 for ADPT Adaptive Biotechnologies Corp
Accepted 2026-08-19 20:15:10 ET · period of report 2026-08-17 · accession 0001780649-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-19 20:15 | 2026-08-17+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | M - OptEx | $6.55 | +600.0K | 2.46M | +32% | +$3.93M |
| DM | 2026-08-19 20:15 | 2026-08-17+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | S - Sale+OE | $24.80 | -600.0K | 2.18M | -22% | -$14.88M |
| DM | 2026-08-19 20:15 | 2026-08-17+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | M - OptEx | $0.00 | -600.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | M | A | 321,324 | $6.55 | 2,501,842 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-17 | S | D | 318,799 | $25.08 | 2,183,043 | D | — | — | (F1) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 3 | Common | Common Stock | 2026-08-17 | S | D | 2,525 | $25.57 | 2,180,518 | D | — | — | (F2) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 4 | Common | Common Stock | 2026-08-18 | M | A | 278,676 | $6.55 | 2,459,194 | D | — | — | |
| 5 | Common | Common Stock | 2026-08-18 | S | D | 278,472 | $24.48 | 2,180,722 | D | — | — | (F3) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 6 | Common | Common Stock | 2026-08-18 | S | D | 204 | $25.14 | 2,180,518 | D | — | — | (F4) The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 7 | Derivative | Stock Option (right to buy) | 2026-08-17 | M | D | 321,324 | $0.00 | 278,676 | D | $6.55 · — to 2028-02-07 | 321,324 Common Stock | (F5) The option was fully vested and exercisable and would have expired on February 7, 2028. |
| 8 | Derivative | Stock Option (right to buy) | 2026-08-18 | M | D | 278,676 | $0.00 | 0 | D | $6.55 · — to 2028-02-07 | 278,676 Common Stock | (F5) The option was fully vested and exercisable and would have expired on February 7, 2028. |